DE69133516D1 - Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen - Google Patents

Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen

Info

Publication number
DE69133516D1
DE69133516D1 DE69133516T DE69133516T DE69133516D1 DE 69133516 D1 DE69133516 D1 DE 69133516D1 DE 69133516 T DE69133516 T DE 69133516T DE 69133516 T DE69133516 T DE 69133516T DE 69133516 D1 DE69133516 D1 DE 69133516D1
Authority
DE
Germany
Prior art keywords
oral administration
atigenigen
auto
treatment
autoimmune diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69133516T
Other languages
English (en)
Other versions
DE69133516T2 (de
Inventor
L Weiner
A Hafler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autoimmune Inc
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of DE69133516D1 publication Critical patent/DE69133516D1/de
Application granted granted Critical
Publication of DE69133516T2 publication Critical patent/DE69133516T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69133516T 1990-10-15 1991-10-15 Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen Expired - Lifetime DE69133516T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59693690A 1990-10-15 1990-10-15
US596936 1990-10-15
PCT/US1991/007542 WO1992006708A1 (en) 1990-10-15 1991-10-15 Treatment of autoimmune diseases by oral administration of autoantigens

Publications (2)

Publication Number Publication Date
DE69133516D1 true DE69133516D1 (de) 2006-05-04
DE69133516T2 DE69133516T2 (de) 2006-08-10

Family

ID=24389347

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69133516T Expired - Lifetime DE69133516T2 (de) 1990-10-15 1991-10-15 Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen

Country Status (13)

Country Link
US (1) US6019971A (de)
EP (1) EP0553291B1 (de)
JP (1) JP2635444B2 (de)
KR (1) KR0140841B1 (de)
AT (1) ATE319474T1 (de)
AU (2) AU9023791A (de)
CA (1) CA2092905C (de)
DE (1) DE69133516T2 (de)
ES (1) ES2258261T3 (de)
HU (1) HUT69942A (de)
IL (1) IL99754A (de)
NO (1) NO314878B1 (de)
WO (1) WO1992006708A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US6645504B1 (en) 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
JP2635444B2 (ja) * 1990-10-15 1997-07-30 オートイミューン インク 自己抗体の経口投与による自己免疫性疾患の治療
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
ES2109362T3 (es) * 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
DE4125400C2 (de) * 1991-07-31 2000-08-17 Edwin Klaus Verwendung von unlöslichem Kollagen zur Behandlung von degenerativen, nicht entzündlichen Gelenkprozessen
BR9306042A (pt) * 1992-02-28 1997-11-18 Autoimmune Inc Método para tratar uma doença auto-immune em um mamifero e formas de dosagens farmacêuticas oral e inalável
EP0662838A4 (de) * 1992-09-25 1996-07-24 Autoimmune Inc Verfahren zur behandlung rheumatoider arthritis mittels typ-ii-kollagen.
ES2095001T5 (es) * 1992-12-22 2001-03-16 Univ Cincinnati Una composicion terapeutica administrable oralmente y su metodo de obtencion.
DK0609471T3 (da) * 1993-02-02 2000-05-29 Edwin Dr Klaus Anvendelse af kollagen til behandling af sygelige ledprocesser
WO1994027634A1 (en) * 1993-06-02 1994-12-08 Institute For Child Health Research Cryptic peptides for use in inducing immunologic tolerance
GB9319429D0 (en) 1993-09-21 1993-11-03 London Health Ass Methods and products for controlling immune responses in mammals
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
EP0871763B1 (de) * 1996-01-05 2009-02-25 Autoimmune, Inc. Methode zur herstellung von type-ii kollagen
WO1997046253A2 (en) * 1996-06-03 1997-12-11 Powderject Vaccines, Inc. Immunotherapy for autoimmune disease
WO1998006861A2 (en) * 1996-08-15 1998-02-19 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7691829B2 (en) * 1998-03-24 2010-04-06 Petito George D Composition and method for healing tissues
US20050208114A1 (en) * 1998-03-24 2005-09-22 Petito George D Composition and method for healing tissues
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7462486B2 (en) * 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
CA2408935A1 (en) * 2000-05-12 2001-11-15 Halina Offner Method of treating immune pathologies with low dose estrogen
AU2001264813B2 (en) 2000-05-24 2005-12-08 The United States Of America, As Represented By Secretary Of The Department Of Health And Human Services Methods for preventing strokes by inducing tolerance to e-selectin
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
WO2006012641A2 (en) * 2004-07-30 2006-02-02 Oregon Health And Science University Methods for detecting and treating autoimmune disorders
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN104922199A (zh) * 2015-07-14 2015-09-23 无限极（中国）有限公司 一种保护骨关节组合物及其应用
WO2018209008A1 (en) 2017-05-11 2018-11-15 Avicenna Nutracetical, Llc Methods for producing collagen
EP4031167A4 (de) * 2019-09-16 2023-07-19 Figene, LLC Behandlung von bandscheibendegenerativen erkrankungen und stimulierung der proteoglykansynthese durch konditionierte fibroblastenmedien und formulierungen davon

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350682A (en) * 1979-05-11 1982-09-21 Lescarden Ltd. Cartilage extraction processes and products
ATE128627T1 (de) * 1986-06-30 1995-10-15 Massachusetts Inst Technology Immunomodulare mittel und deren verwendung.
CA1302880C (en) * 1986-07-25 1992-06-09 Peter Koepff Agents for the treatment of arthroses
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
ATE258065T1 (de) * 1987-06-24 2004-02-15 Brigham & Womens Hospital Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
CA1340012C (en) * 1987-08-17 1998-08-25 Trustees Of Leland Stanford Jr. University Peptide determinant associated with immunity
DK0506785T3 (da) * 1989-12-20 2000-07-24 Autoimmune Inc Forbedret behandling af autoimmune sygdomme ved aerosol-administration af autoantigener
US5075112A (en) * 1990-02-12 1991-12-24 Cartilage Technologies Inc. Method of and dosage unit for inhibiting angiogenesis or vascularization in an animal using shark cartilage
ES2107459T3 (es) * 1990-03-02 1997-12-01 Autoimmune Inc Mejora de la regulacion represora de enfermedades autoinmunes por administracion oral o enteral de autoantigenos.
JP2635444B2 (ja) * 1990-10-15 1997-07-30 オートイミューン インク 自己抗体の経口投与による自己免疫性疾患の治療
DE4125400C2 (de) * 1991-07-31 2000-08-17 Edwin Klaus Verwendung von unlöslichem Kollagen zur Behandlung von degenerativen, nicht entzündlichen Gelenkprozessen

Also Published As

Publication number Publication date
JP2635444B2 (ja) 1997-07-30
NO931372L (no) 1993-05-18
HU9301089D0 (en) 1993-07-28
EP0553291B1 (de) 2006-03-08
IL99754A (en) 1996-08-04
AU9023791A (en) 1992-05-20
AU693232B2 (en) 1998-06-25
IL99754A0 (en) 1992-08-18
HUT69942A (en) 1995-09-28
KR930702026A (ko) 1993-09-08
CA2092905A1 (en) 1992-04-16
EP0553291A1 (de) 1993-08-04
AU3040995A (en) 1995-11-30
EP0553291A4 (en) 1994-11-30
US6019971A (en) 2000-02-01
KR0140841B1 (ko) 1998-06-01
CA2092905C (en) 2002-01-08
NO314878B1 (no) 2003-06-10
ES2258261T3 (es) 2006-08-16
WO1992006708A1 (en) 1992-04-30
ATE319474T1 (de) 2006-03-15
NO931372D0 (no) 1993-04-14
DE69133516T2 (de) 2006-08-10
JPH05508662A (ja) 1993-12-02

Similar Documents

Publication Publication Date Title
DE69133516D1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
ATE130762T1 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
DK0627933T3 (da) Bystander-suppression af autoimmune sygdomme
ATE190496T1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
ATE157257T1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
EA200401473A1 (ru) Предотвращение и лечение амилоидогенного заболевания
ES2185761T3 (es) Metodo para elaborar una preparacion para el blanqueamiento de dientes o el tratamiento de problemas en la piel o trastornos de las membranas mucosas.
DE3873855D1 (de) Mischung von cholecalciferol-derivaten fuer die behandlung von nierenbezogenen knochenkrankheiten.
DE60132444D1 (de) Behandlung von reizkolon-syndrom oder -krankheit
DE69418183T2 (de) Immunotherapeutische zubereitung
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
DE3687233T2 (de) Pharmazeutische zusammensetzungen zur behandlung von hautkrankheiten.
RU94002713A (ru) Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда)
ATE65394T1 (de) Behandlung von knochenschwund.
ATE79541T1 (de) Mischung von cholecalciferol-derivaten fuer die behandlung von nierenbezogenen knochenkrankheiten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition